A. N. Rossolovskiy

A. N. Rossolovskiy

Auto-generated profile, based on publicly available information

A. N. Rossolovskiy

Saratov State Medical University named after V. I. Razumovsky

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2025 in Transplantologiya. The Russian Journal of Transplantation
Verified
Journal Article
Open access
PDF file
VBV. D. Babaev
V. D. Babaev
AKA. V. Kuligin
A. V. Kuligin
АРА. Н. Россоловский
А. Н. Россоловский
RPR. S. Prokhorov
R. S. Prokhorov
ALA. V. Lushnikov
A. V. Lushnikov
EZE. E. Zeulina
E. E. Zeulina
Background. Living related donor (LRD) kidney transplantation is the most effective strategy of renal replacement therapy for patients with stage 5 chronic kidney disease. LRD organs are used due to the shortage of organs from deceased donors. One of the key problems still remained is the anesthetic management of laparoscopic donor nephrectomy (LDNE) and its impact on the graft condition.Objective. Analysis and generalization of the results obtained in the studies of anesthetic management of LDNE and its impact on the graft condition.Material and methods. The literature search was performed in the PubMed, eLibrary, The Cochrane Library, MedLine, EMBASE databases using the search queries: "laparoscopic donor nephrectomy", "nephrectomy", "anesthesia for donor nephrectomy and kidney transplantation", "renal graft condition during anesthesia", which made it possible to find and analyze 445 works published in foreign and Russian journals from 2020 to 2025. As a result of the selection, 51 publications were included in the review, including 10 randomized clinical trials, 1 experimental study, 16 observational studies, 2 meta-analyses, 10 systematic reviews, 1 single-center retrospective controlled study, 5 single-center prospective controlled studies, 4 clinical guidelines, 2 clinical case reports.Conclusion. In the world literature over the recent five years, we have hardly found a large number of reports covering the issue of perioperative anesthetic management of LDNE. The available data indicate that general, combined and regional anesthesia are of interest and can be effectively used in LDNE.

4 May 2022 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
ATA. I. Tarasenko
A. I. Tarasenko
ARA. N. Rossolovskiy
A. N. Rossolovskiy
OBO. L. Berezinets
O. L. Berezinets
Alla BucharskayaAlla Bucharskaya
Alla Bucharskaya
SPS. S. Pakhomiy
S. S. Pakhomiy
Galina MaslyakovaGalina Maslyakova
Galina Maslyakova
Purpose of the study. The study's objective is to investigate the expression level of tissue and serum markers of oncogenesis and nephrofibrosis transforming growth factor beta (TGF‑β) and matrix metalloproteinase‑9 (MMP‑9) in patients operated for various stages of renal cell carcinoma.Materials and methods. The study prospectively included medical data of 60 patients with kidney cancer with T1–3N0M0 who received surgical treatment in the Clinic of Urologynamed after S. R. Mirotvortsev of the State Medical University from 2016 to 2019. The patients were divided into 3 groups: Group 1 included 20 patients who underwent laparoscopic kidney resection; Group 2–20 patients who underwent laparoscopic nephrectomy; Group 3–20 patients who underwent open nephrectomy. The control group consisted of 15 healthy volunteers without chronic kidney diseases. All patients signed an informed consent to participate in the study. All patients at the preoperative stage, in the early (7–10 days) and remote postoperative periods (after 1 and 2 years) were tested by solid‑phase ELISA on a StatFax 4200 analyzer using eBiosence and Cloud‑Clone Corp reagent kits for the serum concentration of oncogenesis markers MMP‑9 and TGF‑β1.Results. Initial increase of MMP‑9 concentration was detected in all groups of PCC patients compared to the control group (p ≤ 0.05). According to the results of ROC analysis, this indicator has high specificity and sensitivity for prognosis of preoperative stage of renal cell carcinoma. The sensitivity and specificity of MMP‑9 were 87.5 % and 62 %, respectively, and the diagnostically significant level of MMP‑9 was 958 ng/ml. A comprehensive analysis of the content of MMP‑9 and TGF‑β1 oncogenesis markers in serum and tumor cells revealed the correlation of these indicators in various biological objects.Conclusion. Markers of oncogenesis and nephrofibrosis TGF‑β1 and MMP‑9 provide an opportunity for non‑invasive monitoring of tumor progression and probability of metastasis in the clinical setting. Serum MMP‑9 are a reliable predictor of tumor growth. Serum TGF‑β1 concentration isn't a sufficiently reliable marker of tumor progression.

23 June 2021 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
ATA. I. Tarasenko
A. I. Tarasenko
ARA. N. Rossolovskiy
A. N. Rossolovskiy
OBO. L. Berezinets
O. L. Berezinets
DDD. A. Durnov
D. A. Durnov
EPE. B. Popyhova
E. B. Popyhova
VPV. M. Popkov
V. M. Popkov
Purpose of the study.To determine the association of individual biomolecular markers of oncogenesis MMP‑2, MMP‑9 and the inhibitor of metalloproteinases TIMP‑1 with the risk of tumor invasion and metastasis in the early and late postoperative period in various types of surgical treatment of RCC.Materials and methods.The study prospectively included medical data of 60 patients with kidney cancer with T1-3N0 M0 who received surgical treatment at the Urology Clinic of the S.R.Mirotvortsev Design Bureau of the SSMU from 2016 to 2019. The patients were divided into 3 groups: 1st group included 20 patients who underwent kidney resection for elective indications, with tumors of the renal parenchyma; 2nd group – 20 patients who underwent radical nephrectomy by laparoscopic approach; Group 3-20 patients who underwent radical nephrectomy with lumbotomy access. All patients being in the early (7-10th day) and long-term postoperative period (after 1 and 2 years) by solid-phase ELISA, on a StatFax 4200 analyzer using eBiosence and Cloud-Clone Corp reagent kits, a study was made on the basis of the concentration in the blood serum of markers of oncogenesis MMP‑2, MMP‑9 and TIMP‑1 metalloproteinase inhibitor.Results.In all groups of patients with RCC, an initial increase in the concentration of MMP‑9 was revealed compared to the control (p≤0.05). According to the results of the ROC analysis, this indicator has a high specificity and sensitivity in terms of predicting RCC at the preoperative stage. The highest sensitivity and specificity for detecting tumor progression was demonstrated by matrix metalloproteinases: MMP‑2 – sensitivity 96 %, specificity 67 % (cut-off point 357.5 pg/ml) and MMP‑9 – sensitivity 87.5 % and specificity 62 % (cut-off point 958 ng/ml). At the same time, TIMP‑1 showed less significant indicators – sensitivity and specificity (74 % and 60 %, respectively) with a cut-off point of 0.49 ng/ml.Conclusion.Serum MMP‑2 and MMP‑9 are a marker of a poor prognosis for the progression of RCC. Elevated levels of MMP‑9 in the blood serum of RCC patients before and after various types of surgical treatment reflect the individual characteristics of the patient’s body and the tumor process. Dynamic monitoring of the level of markers of oncogenesis in patients with RCC allows a personalized approach to the choice of the scope and method of surgical treatment of RCC.